Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
ObjectiveTo evaluate the efficacy and safety of sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma (HCC) to provide a more effective first-line treatment for patients with advanced HCC.MethodsThis open-label, prospective, phase II study incl...
Main Authors: | Dailong Li, Lu Xu, Jinxing Ji, Dan Bao, Juan Hu, Ying Qian, Yinjie Zhou, Zhuo Chen, Daojun Li, Xiaopeng Li, Xiaoling Zhang, Hao Wang, Changjun Yi, Menglu Shi, Yaqi Pang, Siqi Liu, Xinhua Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.944062/full |
Similar Items
-
Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
by: Le Zhang, et al.
Published: (2023-03-01) -
Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China
by: Zhe Xu, et al.
Published: (2023-07-01) -
Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats
by: Su-su Bao, et al.
Published: (2023-09-01) -
Efficacy and Safety of Fruquintinib Combined with Sintilimab in Treatment of Advanced Microsatellite Stable Colorectal Cancer
by: LI Shan, et al.
Published: (2023-12-01) -
Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage
by: WenJuan Wang, et al.
Published: (2024-02-01)